325 related articles for article (PubMed ID: 10604732)
1. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
Mitry E; Baudin E; Ducreux M; Sabourin JC; Rufié P; Aparicio T; Aparicio T; Lasser P; Elias D; Duvillard P; Schlumberger M; Rougier P
Br J Cancer; 1999 Dec; 81(8):1351-5. PubMed ID: 10604732
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
Kulke MH; Wu B; Ryan DP; Enzinger PC; Zhu AX; Clark JW; Earle CC; Michelini A; Fuchs CS
Dig Dis Sci; 2006 Jun; 51(6):1033-8. PubMed ID: 16865563
[TBL] [Abstract][Full Text] [Related]
4. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
Fjällskog ML; Granberg DP; Welin SL; Eriksson C; Oberg KE; Janson ET; Eriksson BK
Cancer; 2001 Sep; 92(5):1101-7. PubMed ID: 11571721
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Nakano K; Takahashi S; Yuasa T; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Tsuyama N; Ishikawa Y; Hatake K
Jpn J Clin Oncol; 2012 Aug; 42(8):697-703. PubMed ID: 22701038
[TBL] [Abstract][Full Text] [Related]
6. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
[TBL] [Abstract][Full Text] [Related]
7. The treatment of undifferentiated neuroendocrine tumors.
Mitry E; Rougier P
Crit Rev Oncol Hematol; 2001 Jan; 37(1):47-51. PubMed ID: 11164718
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy of neuroendocrine tumors].
Droz JP; Flechon A; Lombard-Bohas C
Rev Prat; 2002 Feb; 52(3):285-9. PubMed ID: 11925719
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Balasubramaniam S; Redon CE; Peer CJ; Bryla C; Lee MJ; Trepel JB; Tomita Y; Rajan A; Giaccone G; Bonner WM; Figg WD; Fojo T; Piekarz RL; Bates SE
Anticancer Drugs; 2018 Jun; 29(5):457-465. PubMed ID: 29420340
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
11. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
Turner NC; Strauss SJ; Sarker D; Gillmore R; Kirkwood A; Hackshaw A; Papadopoulou A; Bell J; Kayani I; Toumpanakis C; Grillo F; Mayer A; Hochhauser D; Begent RH; Caplin ME; Meyer T
Br J Cancer; 2010 Mar; 102(7):1106-12. PubMed ID: 20234360
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.
Hatton MQ; Reed NS
Clin Oncol (R Coll Radiol); 1997; 9(6):385-9. PubMed ID: 9448967
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.
Papandreou CN; Daliani DD; Thall PF; Tu SM; Wang X; Reyes A; Troncoso P; Logothetis CJ
J Clin Oncol; 2002 Jul; 20(14):3072-80. PubMed ID: 12118020
[TBL] [Abstract][Full Text] [Related]
16. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
[TBL] [Abstract][Full Text] [Related]
17. Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer.
Chewaskulyong B; Thongprasert S
J Med Assoc Thai; 1998 Jan; 81(1):37-41. PubMed ID: 9470320
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
[TBL] [Abstract][Full Text] [Related]
19. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases.
Patta A; Fakih M
Anticancer Res; 2011 Mar; 31(3):975-8. PubMed ID: 21498724
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
